Press release
AXS-05 for Treatment-Resistant Depression: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players - Axsome Therapeutics
DelveInsight has released a comprehensive report titled "AXS-05 Market Forecast" offering a thorough examination and predictive insights into the AXS-05 market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.The extensive report offers a thorough examination of the market potential and market share of AXS-05 in the therapeutics landscape for Treatment-Resistant Depression across the 7MM spanning the years 2019 to 2032. By delving into this analysis, stakeholders gain valuable insights into the evolving landscape of AXS-05, encompassing both clinical and commercial dimensions. Key parameters such as the drug's Mechanism of Action (MOA), Route of Administration (ROA), dosage, and any special designations are meticulously explored, providing a holistic understanding of its profile.
AXS-05 Drug Insights
AXS-05 represents a groundbreaking advancement in the realm of pharmacology, offering a unique oral formulation with investigational properties as an NMDA receptor antagonist. This innovative compound harnesses the combined therapeutic potential of dextromethorphan (DM) and bupropion in a proprietary blend, demonstrating multimodal activity. Its development is specifically geared towards addressing a spectrum of central nervous system (CNS) conditions, showcasing promise as a potential treatment option in this complex therapeutic landscape.
The ongoing development of AXS-05 marks a significant milestone in the field of neuropsychiatry, with its potential applications extending to the treatment of major depressive disorder (MDD), Alzheimer's disease agitation, and smoking cessation. Notably, the compound has garnered notable recognition from the FDA, securing Breakthrough Therapy designation for its efficacy in managing both MDD and Alzheimer's disease agitation. This acknowledgment underscores the compound's promising therapeutic profile and the pressing need for innovative solutions in addressing these challenging neurological conditions.
Get a detailed overview of the AXS-05 drug and stay ahead of the competition by leveraging key insights:
https://www.delveinsight.com/sample-request/axs-05-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Key Highlights of the AXS-05 Market Report
• The report includes a projected assessment of AXS-05 sales for Treatment-Resistant Depression up to the year 2032.
• The report offers in-depth coverage of advanced-stage emerging therapies for the treatment of Treatment-Resistant Depression.
• The report additionally includes both qualitative and quantitative analyses conducted by analysts, along with Key Opinion Leader (KOL) perspectives on AXS-05 for Treatment-Resistant Depression.
Why AXS-05 Market Report?
• The projected market data for AXS-05 in the context of Treatment-Resistant Depression will play a crucial role in informing decision-making related to the therapeutic portfolio. It will provide valuable insights into the overall landscape of AXS-05, aiding in strategic planning and decision-making processes within the therapeutic domain.
• A comprehensive market forecast for AXS-05 will contribute to a better understanding of how the drug competes with other emerging therapies within the therapeutics landscape. This analysis will provide insights into the drug's positioning, potential market share, and overall impact on the competitive environment in the therapeutic field.
• The report additionally offers future market assessments for the AXS-05 market in the field of Treatment-Resistant Depression across the 7 Major Markets. It encompasses advanced qualitative analyses such as SWOT analysis, insights from expert analysts, a comprehensive overview of market competitors, and a brief analysis of other emerging therapies within the realm of Treatment-Resistant Depression. This multifaceted approach ensures a comprehensive understanding of the AXS-05 market landscape, combining both quantitative and qualitative perspectives for a well-rounded assessment.
• Conducting a thorough market forecast for AXS-05 will facilitate a detailed analysis of the drug's clinical trial progress. This examination will encompass a comprehensive assessment of the clinical, regulatory, and commercial aspects, providing valuable insights into the advancements of AXS-05.
Explore key clinical, commercial, and regulatory milestones associated with AXS-05 by visiting:
https://www.delveinsight.com/sample-request/axs-05-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Contents of the Report
1. Report Introduction
2. AXS-05 Overview in Treatment-Resistant Depression
3. Competitive Landscape (Key Assessment of the Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies Analysis)
5. AXS-05 Market Assessment
6. SWOT Analysis
7. Analysts' Views
8. Appendix
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
* The final table of contents may be subject to change based on user demand.
Request the Sample PDF to Learn More About the Key Offerings of the AXS-05 Market Report @
https://www.delveinsight.com/sample-request/axs-05-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
----------------------------------------------------------------------------------------------------------------------------------
Other Related Reports By DelveInsight
Treatment-Resistant Depression Pipeline Insight
DelveInsight's "Treatment-Resistant Depression Pipeline Insight" report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Treatment-Resistant Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by routes of administration, and molecule types. Furthermore, it further highlights the inactive pipeline products in this space. Some of the key companies in the Treatment-Resistant Depression Therapeutics market include Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, and ATAI Life Sciences, and others.
Visit & explore how the Treatment-Resistant Depression therapeutics pipeline is evolving, at:
https://www.delveinsight.com/report-store/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release AXS-05 for Treatment-Resistant Depression: Market Size and Share Analysis and Competitive Landscape by DelveInsight | Key Players - Axsome Therapeutics here
News-ID: 3379811 • Views: …
More Releases from DelveInsight Business Research LLP
Alpha-1 Protease Inhibitor Deficiency Market Size 2032: CSL Behring, Grifols The …
DelveInsight's "Alpha-1 Protease Inhibitor Deficiency Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Alpha-1 Protease Inhibitor Deficiency, historical and forecasted epidemiology as well as the Alpha-1 Protease Inhibitor Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Alpha-1 Protease Inhibitor Deficiency Market Research Report
• The increase in Alpha-1 Protease Inhibitor Deficiency Market Size…
Amyloidosis Market Size Report 2032: Attralus Inc., Novotech Pty Limited, Criter …
DelveInsight's "Amyloidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Amyloidosis, historical and forecasted epidemiology as well as the Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Amyloidosis Market Research Report
• The increase in Amyloidosis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies…
Basal Cell Nevus Syndrome Market Size Report 2032: Latest FDA Approvals, Emergin …
DelveInsight's "Basal Cell Nevus Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Nevus Syndrome, historical and forecasted epidemiology as well as the Basal Cell Nevus Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Basal Cell Nevus Syndrome Market Research Report
• The increase in Basal Cell Nevus Syndrome Market Size…
Biliary Atresia Market Size Report 2032: Latest FDA Approvlas and Pipeline Repor …
DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Key Takeaways from the Biliary Atresia Market Research Report
• The increase in Biliary Atresia Market Size is a direct consequence of the increasing…
More Releases for Depression
Increase in the prevalence of anxiety disorders and depression is bolstering the …
The research report "Global Anxiety Disorders and Depression Treatment Market: By Product Type (MAOIs (Monoamine Oxidase inhibitors), Atypical Antipsychotics, Benzodiazepines, Anticonvulsants, Beta-Blockers, SRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TeCAs (Tetracyclic Antidepressants), TCAs (Tricyclic Antidepressants), Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Others), and Geography- Global/Region/Country Forecast to 2028." The global anxiety disorders and depression treatment market size was valued at USD 8.2 Bn in the year…
Depression Treatment Device Market: Information by Product Type (Light Therapies …
Depression is characterized by multiple mental health challenges that involve a lack of positivity, suicidal thoughts, insomnia, anxiety, loss of appetite, and sadness. Depression is caused by a combination of biological, genetic, environmental, and psychological factors. Globally, the prevalence of depression is increasing at an alarming rate. About 300 million people of all ages suffered from depression and the suicide rate rose to about 8,00,000 individuals in 2018. As per…
Depression Cannot Hit A Moving Target
Cottonwood Heights, Utah, Mar 12, 2020 -- Depression can't hit a moving target. That was a phrase to live by for Chelsea Hansen. She was full of life and love, and she had big goals. But soon she was to discover that life doesn't turn out the way she planned.
Behind the Fake Smile is a fictional book based on real-life experiences. It's the story of how Chelsea navigates a world…
Depression Drugs Market: Increase in Cases of Depression to Boost Market Growth
Transparency Market Research (TMR) has published a new report titled, “Depression Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global depression drugs market was valued at US$ 6,500 Mn in 2017 and is anticipated to decline at a CAGR of 2% from 2018 to 2026. The report suggests that rise in incidence of major depression disorders is projected to drive…
Depression Therapeutics Market Forecast till 2025
Antidepressants are used to treat a wide range of mental disorders, including depression, anxiety, and major depressive disorder. Certain neurotransmitters in the brain exist in chemical form such as dopamine and serotonin, which are responsible for maintaining emotional balance such as mood and behavior. Antidepressants cover a wide range of drug categories, including selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants…
Depression Drug Market: Global Depression Drug Forecast Will Reach $16.8 billion …
Zion Market Research has published a new report titled “Depression Drug (Benzodiazepines, SNRIs, TCAs, TeCAs, Atypical Antipsychotics, Monoamine Oxidase inhibitors and Others) Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2014 – 2020” According to the report, the global depression drug market was valued at USD 14.51 billion in 2014 and is expected to generate revenue of USD 16.8 billion by end of 2020, growing at a CAGR of 2.50%…
